Design and synthesis of curcumin-bioconjugates to improve systemic delivery

Sanjay Kumar, Krishna K Dubey, Snehlata Tripathi, Masayuki Fujii and Krishna Misra
Nucleic Acids Research Laboratory, Department of Chemistry, University of Allahabad, Allahabad-211 002, India and Bioorganic Chemistry Laboratory, Department of Biological and Environmental Chemistry, Kyushu School of Engineering, Kinki University, 11-6 Kayanomori, Iizuka, Fukuoka 820-8555, Japan

ABSTRACT
Di-O-glycinoyl curcumin (I), di-O-glycinoyl-C₄-glycyl-curcumin (II), 5'-deoxy-5'-curcuminyl thymidine (5'-cur-T) (III) and 2'-deoxy-2'-curcuminyl uridine (2'-cur-U) (IV) have been synthesized and characterised by elemental analysis & ¹H NMR. The antibacterial activities of these four bioconjugates has been tested particularly for multiresistant micro-organisms. Best results are shown by I & IV. These bioconjugates serve dual purpose of systemic delivery as well as therapeutic agents against viral diseases.

INTRODUCTION
The meager absorption of curcumin through the intestinal wall on oral intake needs to be improved in order to achieve significant concentration inside the cells for appropriate activity henceforth, the nucleoside-curcumin bioconjugate can serve dual purpose of systemic delivery as well as therapeutic agent against viral diseases.

MATERIALS AND METHOD
Curcumin, glycine, allyl bromide and triphenylphosphite were purchased from Merck-Schuchardt, Germany. Nucleosides were purchased from Sigma Chemical Company, USA. Mueller-Hinton Broth, Agar and sterile discs were purchased from Hi Media laboratory Ltd., Mumbai, India.

RESULT AND DISCUSSION
Di-O-glycinoyl curcumin (I), di-O-glycinoyl-C₄-glycyl-curcumin (II) were synthesized by condensing curcumin with N-phthaloyl glycinoyl chloride in anhydrous pyridine. In case of (II) a strong base NaOEt was taken whereas in case of (I) curcumin itself was treated with N-phthaloyl glycinoyl chloride. 5'-Deoxy-5'-curcuminyl thymidine (5'-cur-T) (III) and 2'-deoxy-2'-curcuminyl uridine (2'-cur-U) (IV) were synthesized by taking 5'-deoxy-5'-bromothymidine and 2'-deoxy-2'-chloro uridine in pyridine mixed with sodium salt of (I). The antibacterial activity of bioconjugates (I), (II), and (IV) were compared with curcumin from known macro-dilution broth susceptibility test method. These were serially diluted (30, 15, 7.5, 3.75, 1.88, 0.94 μmol/L) and made in Muller-Hinton broth, after which a standardized bacterial suspension was added. The lowest concentration of curcumin bioconjugates in μmol/mL that prevent the in vitro growth of micro-
organism has been represented as MIC (Minimum Inhibitory Concentration, shown in Table 1.

\[
\begin{align*}
\text{Curcumin conjugates} \\
\text{I} & : R_1 = R_3 = \text{CO-CH}_2\text{-NH}_2, R_2 = \text{H} \\
\text{II} & : R_1 = R_2 = R_3 = -\text{CO-CH}_2\text{-NH}_2 \\
\text{III} & : R_1 = R_2 = \text{H}, R_2 = 5'-\text{Deoxy thymidine} \\
\text{IV} & : R_1 = R_3 = \text{H}, R_2 = 2'-\text{Deoxy uridine}
\end{align*}
\]

Each test was performed in triplicate and the MICs reported represent the result of at least two repetitions. Out of four, three conjugates show positive result on multi-resistant micro-organisms. The most encouraging result was found against *Streptococcus pyogenis* with (I) having MIC 1.88 µmol/mL against *Streptococcus pyogenes* and compared with one of the best marketed antibiotic, viz. Amoxycilv which show MIC 7 µmol/mL (6 µmol/mL reported) where as (I) shows MIC 1.88 µmol/mL which is 3.7 times more effective than amoxyclav. The results with 5'-deoxy-5'-curcuminoyl thymidine (III) were not satisfactory among the selected bacterial strains, which may be due the fact that thymidine is not a natural component of bacterial DNA (data not shown).

CONCLUSION

It is apparent from the above discussion that the amino acid bioconjugates are bacteriologically more active than nucleoside bioconjugate, since amino acid is the main component of bacterial cell wall.

ACKNOWLEDGEMENT

Authors are highly thankful to Department of Science & Technology (DST), New Delhi, India for financial Assistance.

REFERENCES


Table 1

<table>
<thead>
<tr>
<th>S.No</th>
<th>Name of Bacteria</th>
<th>I</th>
<th>II</th>
<th>IV</th>
<th>Cur</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td><em>Escherichia cloacae</em></td>
<td>3.75</td>
<td>7.50</td>
<td>15.0</td>
<td>R</td>
</tr>
<tr>
<td>2</td>
<td><em>Peptococcus anaerobe</em></td>
<td>3.75</td>
<td>7.50</td>
<td>30.0</td>
<td>R</td>
</tr>
<tr>
<td>3</td>
<td><em>Staphylococcus epidermidis</em></td>
<td>15.0</td>
<td>15.0</td>
<td>7.50</td>
<td>R</td>
</tr>
<tr>
<td>4</td>
<td><em>Staphylococcus saprophyticus</em></td>
<td>3.75</td>
<td>30.0</td>
<td>15.0</td>
<td>R</td>
</tr>
<tr>
<td>5</td>
<td><em>Micro coci</em></td>
<td>3.75</td>
<td>15.0</td>
<td>3.75</td>
<td>R</td>
</tr>
<tr>
<td>6</td>
<td><em>Staphylococcus aureus</em></td>
<td>15.0</td>
<td>30.0</td>
<td>7.50</td>
<td>R</td>
</tr>
<tr>
<td>7</td>
<td><em>Streptococcus pyogenes</em></td>
<td>1.88</td>
<td>3.75</td>
<td>15.0</td>
<td>15.0</td>
</tr>
</tbody>
</table>

MIC Correlation Diagram (in µmol/mL) I = Di-O-glycinoyl curcumin, II = di-O-glycinoyl-C^-glycyl-curcumin and IV = 2'-deoxy-2'-curcuminyl uridine (2'-cur-U), Cur = Curcumin, R = Resistant (below 10 mm). I shows best result against *Streptococcus pyogenes*. Results with 5'-deoxy-5'-curcuminyl thymidine (5'-Cur-I) are not included.